A Thousand Tiny Pieces: The Federal Circuit’s Fractured Myriad Ruling, Lessons to Be Learned, and the Way Forward
Jonathan R. K. Stroud
Finnegan, Henderson, Farabow, Garrett & Dunner LLP; American University Washington College of Law
September 20, 2011
IP Theory, Vol. 3, 2012
American University, WCL Research Paper
The Supreme Court granted, vacated, and remanded the infamous Ass’n of Molecular Pathology v. U.S. Patent & Trademark Office (Myriad I), gene-isolation patentability case to the Court of Appeals for the Federal Circuit (CAFC) in light of the recent Prometheus decision, which held 9-0 that a certain diagnostic method was invalid subject matter because it was an abstract idea merely modified by other obvious steps. This Article argues that Myriad should be affirmed again by the Federal Circuit, particularly in light of Prometheus, in order to inject certainty, clarity, and consistency into the § 101 patentable subject matter jurisprudence.
Number of Pages in PDF File: 24
Keywords: Myriad, Genetics, Diagnostics, Patents, Subject-Matter, 101, Prometheus, GVR, FDA, Court of Appeals for the Federal Circuit, Federal Circuit, AMP v. USPTOAccepted Paper Series
Date posted: April 22, 2012
© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo2 in 0.687 seconds